$2.76
-0.03 (-1.08%)
Open$2.80
Previous Close$2.79
Day High$2.82
Day Low$2.74
52W High$5.46
52W Low$2.32
Volume—
Avg Volume404.0K
Market Cap95.95M
P/E Ratio—
EPS$-0.31
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+450.0% upside
Current
$2.76
$2.76
Target
$15.18
$15.18
$12.50
$15.18 avg
$18.81
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.06M | 11.02M | 11.79M |
| Net Income | 2.28M | 2.12M | 2.45M |
| Profit Margin | 18.9% | 19.3% | 20.8% |
| EBITDA | 3.37M | 3.22M | 3.75M |
| Free Cash Flow | 1.70M | 2.02M | 1.47M |
| Rev Growth | +16.3% | -0.5% | +13.7% |
| Debt/Equity | 1.56 | 1.35 | 1.56 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |